Insulin resistance in perimenopause: why it rises before menopause

Your cycles are still coming. Your fasting glucose is still normal. Your weight may be up only 3 to 7 lb (1.4 to 3.2 kg), or maybe it has not changed at all. But your waist is different, your post-meal energy is less predictable, and labs that used to look effortless now need a closer read.

For the perimenopause-specific muscle timeline, see Muscle loss in perimenopause: how early does it start?.

This is a common perimenopause pattern: insulin resistance can begin rising before menopause is official. The shift is not just “getting older” and it is not only about weight gain. It is the combined effect of changing ovarian hormones, visceral fat redistribution, sleep disruption, muscle loss, stress physiology, and pancreatic compensation.

The important part is timing. By the time fasting glucose or HbA1c crosses into the prediabetes range, the body may have been compensating with higher insulin for years. In perimenopause, that silent compensation can accelerate because several protective systems change at once.

This guide explains why insulin resistance rises during perimenopause, how to test it before glucose looks abnormal, and which levers are most useful in the transition years.

What you’ll learn:

Why insulin resistance can rise before menopause, even with normal glucose
How estrogen, progesterone, visceral fat, sleep, and muscle interact
Which labs are most useful: fasting insulin, HOMA-IR, glucose, HbA1c, and lipids
What to do when your numbers are drifting but not yet diagnostic
How to track the metabolic transition with SuperAge

The short answer

Insulin resistance often rises in perimenopause because the body loses some of the metabolic buffering that supported glucose control in earlier adulthood.

The main drivers are:

Estradiol becomes erratic, then declines, reducing support for insulin signaling, fat distribution, vascular function, and muscle metabolism.
Progesterone falls earlier, worsening sleep for many women, which can raise cortisol and impair glucose control.
Fat shifts toward the abdomen, even when scale weight is stable. Visceral fat is more inflammatory and more insulin-resistant than hip and thigh fat.
Lean mass becomes harder to maintain, reducing the largest storage site for glucose after meals.
Relative androgen balance changes, which is linked in SWAN data to higher metabolic syndrome risk during the menopause transition.

The result is not always high glucose at first. Early on, the pancreas often makes more insulin to keep glucose normal. That is why a woman can have a fasting glucose of 88 mg/dL (4.9 mmol/L) and still show early metabolic strain if fasting insulin or HOMA-IR is elevated.

For the broader transition context, see perimenopause and biological age. For the standalone metabolic marker, see fasting insulin as a longevity biomarker.

For the body-composition side of the same problem, compare weight gain in perimenopause vs aging before assuming every pound is simple fat gain.

Why perimenopause is a metabolic transition, not just a reproductive one

Menopause is defined retrospectively: 12 months without a period. Perimenopause is the years before that point, when cycles become less predictable and reproductive hormones fluctuate. The Menopause Society describes this transition as a time when symptoms such as hot flashes, night sweats, sleep disruption, migraine changes, mood symptoms, and brain fog often appear before menopause itself.

Metabolically, the transition is just as active. Longitudinal data from the Study of Women’s Health Across the Nation (SWAN) show that body composition, fat distribution, sex hormone patterns, lipids, and diabetes risk shift across the menopause transition. These changes often start before the final menstrual period.

That matters because insulin resistance is not a single lab value. It is a system state:

Muscle, liver, and fat cells respond less efficiently to insulin.
The pancreas compensates by producing more insulin.
Glucose stays normal for a while.
Triglycerides, waist size, blood pressure, sleep, and energy can worsen before diabetes criteria are met.
Eventually, if compensation fails, fasting glucose and HbA1c rise.

Perimenopause can push this system because several inputs change together. A little less sleep, a little more abdominal fat, a little less muscle, and a more erratic hormone environment can add up quickly.

The hormone mechanisms: why insulin sensitivity changes before the final period

Estradiol supports glucose handling

Estradiol is not only a reproductive hormone. It helps regulate fat distribution, mitochondrial function, vascular biology, inflammation, and insulin signaling. During perimenopause, estradiol does not simply decline in a smooth line. It can swing high and low, then eventually falls more consistently as the final menstrual period approaches.

That erratic signaling may explain why some women notice metabolic symptoms before a single estradiol or FSH test looks “menopausal.” A one-time blood draw can miss the instability.

SWAN research on estradiol and FSH trajectories found that lower premenopausal estradiol levels and a slower early-transition rise in FSH were associated with higher diabetes risk over follow-up. The point is not that one hormone number diagnoses insulin resistance. The point is that the transition pattern itself carries metabolic information.

For hormone-test context, see FSH vs estradiol vs AMH in perimenopause.

Progesterone decline can worsen sleep

Progesterone often becomes less reliable before estradiol permanently falls. Lower luteal-phase progesterone can make sleep lighter, increase premenstrual symptoms, and reduce resilience to stress.

Poor sleep is directly metabolic. Even a few nights of short or fragmented sleep can reduce insulin sensitivity, increase hunger signaling, and raise next-day glucose variability. In real life, the pattern is not one bad night. It is months of night sweats, early waking, stress, and inconsistent recovery.

That is why sleep is not a soft lifestyle footnote in perimenopause. It is part of the glucose-control system.

Relative androgen balance can shift

Another SWAN analysis found that as estradiol declines more than testosterone, the testosterone-to-estradiol ratio can rise during the menopause transition. Higher baseline ratio and a faster rise were associated with greater incident metabolic syndrome risk.

This does not mean testosterone is “bad” for women. It means the balance between ovarian hormones changes, and that balance can interact with waist size, insulin, triglycerides, HDL cholesterol, and blood pressure.

Visceral fat: the waist change that matters more than the scale

Many women describe perimenopause as a body-shape change before they describe it as weight gain. Pants fit differently. Waist circumference increases. A previously stable midsection becomes more responsive to stress, alcohol, sleep debt, and carbohydrate load.

This matters because abdominal and visceral fat are metabolically different from subcutaneous fat on hips and thighs. Visceral fat releases inflammatory cytokines and free fatty acids into the portal circulation, increasing liver insulin resistance and triglyceride production. That can raise fasting insulin before fasting glucose moves.

The transition can also change body composition without a dramatic scale shift. A woman can lose 2 lb (0.9 kg) of lean mass and gain 2 lb (0.9 kg) of fat and see no change on the scale, while her insulin sensitivity worsens.

Useful tracking:

Metric	Why it helps	Practical cadence
Waist circumference	Best low-cost proxy for abdominal fat	Monthly
Waist-to-height ratio	Adjusts waist for body size	Every 1 to 3 months
DEXA or body composition scan	Shows lean mass and fat distribution	Every 12 to 24 months
Triglycerides and HDL	Often shift with insulin resistance	Every 6 to 12 months
Fasting insulin and HOMA-IR	Shows compensation before glucose rises	Every 6 to 12 months if drifting

For a deeper body-composition strategy, see how to reduce visceral fat.

The lab pattern: normal glucose, higher insulin

The most common early perimenopause pattern is not obvious diabetes. It is normal glucose with higher insulin.

That can look like:

Fasting glucose: 86 to 99 mg/dL (4.8 to 5.5 mmol/L)
HbA1c: 5.2 to 5.6%
Fasting insulin: 8 to 18 microIU/mL
HOMA-IR: above the person’s prior baseline, often above 1.5 to 2.0
Triglycerides: creeping upward
HDL cholesterol: drifting downward
Waist circumference: up 1 to 3 inches (2.5 to 7.6 cm)

The glucose result may still be green on the lab portal because compensation is working. The pancreas is producing enough insulin to keep fasting glucose in range. That does not mean the system is unchanged. It means glucose is the output, while insulin is the pressure needed to produce that output.

For the full discordant-pattern guide, see fasting glucose normal but insulin high.

What to ask for

If you are in your 40s or early 50s and suspect perimenopausal metabolic drift, consider discussing this panel with a clinician:

Test	What it shows
Fasting glucose	Diagnostic glucose baseline
Fasting insulin	Pancreatic compensation
HOMA-IR	Combined fasting insulin and glucose estimate
HbA1c	Average glycation over roughly 2 to 3 months
Lipid panel plus ApoB	Cardiometabolic risk and particle burden
Triglycerides and HDL	Insulin-resistance pattern
ALT and GGT	Liver stress and fatty liver context
TSH, free T4, and thyroid antibodies if symptomatic	Thyroid overlap with fatigue, weight, and cycle changes

American Diabetes Association diagnostic thresholds still matter: fasting glucose 100 to 125 mg/dL (5.6 to 6.9 mmol/L), HbA1c 5.7 to 6.4%, or 2-hour OGTT glucose 140 to 199 mg/dL (7.8 to 11.0 mmol/L) fall in the prediabetes range. But those thresholds are not designed to catch early compensation.

HOMA-IR formula

With US units:

HOMA-IR = fasting insulin x fasting glucose / 405

Example: fasting insulin 12 microIU/mL and fasting glucose 92 mg/dL:

12 x 92 / 405 = 2.7

That pattern suggests the body is using more insulin than ideal to keep glucose normal. It is not a diagnosis by itself, but it is worth repeating and discussing in context.

For a marker comparison, see fasting insulin vs HbA1c vs glucose.

Why this matters for biological age

Insulin resistance is one of the clearest metabolic links between midlife and biological aging. Chronically high insulin and impaired glucose handling can accelerate aging through several pathways:

Glycation: more glucose exposure means more advanced glycation end products, which stiffen blood vessels and connective tissue.
Inflammation: visceral fat and hyperinsulinemia contribute to chronic low-grade inflammatory signaling.
Mitochondrial stress: insulin-resistant muscle has poorer fuel flexibility and lower oxidative capacity.
Autophagy suppression: high insulin keeps cells in a fed-state signal, reducing cellular cleanup.
Vascular aging: insulin resistance clusters with higher blood pressure, triglycerides, ApoB, and endothelial dysfunction.

Perimenopause is a special window because the same drivers also affect biological-age inputs: glucose, inflammation, albumin, lipids, kidney markers, sleep, resting heart rate, HRV, and body composition.

That is why the goal is not to “beat menopause.” The goal is to notice the metabolic slope early, then flatten it before the lab pattern becomes harder to reverse.

For the broader aging frame, see menopause and biological age acceleration and metabolic health and aging.

What actually helps in perimenopause

1. Lift heavy enough to preserve muscle

Skeletal muscle is the largest insulin-sensitive glucose sink. After meals, muscle is where a large share of glucose should go. If lean mass declines and training intensity drops, glucose disposal gets worse even if body weight stays similar.

Aim for 2 to 4 strength sessions per week, built around progressive overload. The goal is not soreness. It is maintaining or increasing muscle in legs, hips, back, and trunk. If you are new to lifting, start with coaching, machines, or a simple full-body plan.

2. Keep protein high enough

Many women under-eat protein during the exact decade when muscle becomes harder to maintain. A practical target is often 0.7 to 1.0 g per lb (1.6 to 2.2 g/kg) of goal body weight per day, adjusted for kidney disease, medical advice, and appetite. Spread it across meals rather than saving most of it for dinner.

3. Put carbohydrates around activity

Perimenopause does not require carbohydrate fear. It does require timing and quality. Higher-fiber carbohydrates, legumes, intact grains, fruit, and starchy vegetables usually behave differently from refined starches and liquid sugar.

For many women, the same carbohydrate load produces a smaller glucose and insulin demand when it follows resistance training, a brisk walk, or a higher-protein meal.

4. Use walking as glucose disposal

A 10 to 20 minute walk after meals is low-tech and effective. It increases muscle glucose uptake through contraction-mediated pathways that do not require much insulin. This is especially useful at dinner, when larger meals, alcohol, and evening cortisol can combine.

5. Protect sleep like a metabolic intervention

If hot flashes, night sweats, anxiety, or early waking are disrupting sleep, treat that as part of metabolic care. Practical basics matter: cool bedroom, consistent wake time, morning light, reduced alcohol, and earlier caffeine cutoff. If symptoms remain severe, discuss perimenopause-specific treatment options with a qualified clinician.

6. Recheck, do not overreact

One elevated fasting insulin result after poor sleep, illness, heavy training, or travel is not a diagnosis. Repeat it under better conditions. Look for a pattern across 2 or 3 data points, paired with waist, lipids, blood pressure, and symptoms.

7. Discuss medication or hormone therapy when appropriate

Some women need more than lifestyle changes, especially with prior gestational diabetes, PCOS, strong family history, rising A1c, or obesity. Options such as metformin, anti-obesity medications, or menopause hormone therapy require individualized medical guidance. The evidence is nuanced, and risk-benefit depends on timing, symptoms, uterus status, clot risk, breast cancer history, migraine pattern, and cardiovascular profile.

This article is educational and not a substitute for medical care. If glucose, HbA1c, insulin, or symptoms are concerning, review them with a clinician who understands both metabolic health and the menopause transition.

How SuperAge helps you track the transition

Perimenopausal insulin resistance is easy to miss when every metric lives in a separate place. A sleep app shows rough nights. A lab portal shows glucose. A wearable shows resting heart rate and HRV. A notes app has cycle symptoms. None of those alone explains the pattern.

SuperAge helps by putting the trend together:

Blood markers: fasting glucose, HbA1c, fasting insulin, triglycerides, HDL, ApoB, ALT, and GGT.
Wearable signals: resting heart rate, HRV, sleep duration, sleep consistency, and workout load from Apple Health.
Body-composition context: weight trend, waist notes, and lean-mass direction when available.
Biological-age framing: metabolic changes are interpreted as part of the broader aging trajectory, not as isolated lab flags.

The most useful perimenopause question is not “Was this one number normal?” It is “Is my trend changing faster than it used to?” That is the level where early action becomes possible.

Frequently asked questions

Can perimenopause cause insulin resistance if I have not gained weight?

Yes. Weight gain is common, but it is not required. Insulin sensitivity can worsen because of sleep disruption, hormone fluctuation, lower lean mass, stress physiology, and fat redistribution toward the abdomen. Scale weight can stay stable while waist circumference and fasting insulin rise.

Is fasting insulin a standard diagnostic test?

No. NIDDK notes that health professionals may not routinely test for insulin resistance, and direct insulin-resistance testing is used mostly in research. Clinically, fasting insulin and HOMA-IR are best used as pattern-reading tools, not stand-alone diagnoses.

What is the best test for insulin resistance in perimenopause?

There is no single perfect test. For practical screening, fasting insulin plus fasting glucose lets you calculate HOMA-IR. HbA1c and fasting glucose show glycemic status. An oral glucose tolerance test or CGM can reveal post-meal patterns that fasting labs miss. The best choice depends on symptoms, risk factors, and what your clinician is willing to order.

Does hormone therapy improve insulin resistance?

Some trials and reviews suggest menopause hormone therapy can have favorable effects on insulin resistance and body composition when used in appropriate candidates, especially closer to the menopause transition. It is not prescribed solely as a glucose-control drug, and it is not appropriate for everyone. The decision should be individualized with a clinician.

Should I use a CGM in perimenopause?

A CGM can be useful if you want to see post-meal patterns, especially if HbA1c is borderline, fasting insulin is high, or symptoms suggest reactive highs and lows. It does not measure insulin, so it complements rather than replaces fasting insulin. See CGM vs fasting insulin for the tradeoffs.

When should I be more urgent?

Seek medical guidance promptly if fasting glucose is repeatedly 126 mg/dL (7.0 mmol/L) or higher, HbA1c is 6.5% or higher, you have symptoms of diabetes, you have a history of gestational diabetes, or your numbers are rising quickly. Also discuss care earlier if you have PCOS, strong family history, high triglycerides, fatty liver, hypertension, or rapid waist gain.

Key takeaways

Insulin resistance can rise during perimenopause before menopause is official and before fasting glucose becomes abnormal.
The main drivers are hormone fluctuation, visceral fat redistribution, sleep disruption, lean-mass loss, stress physiology, and changing androgen-estrogen balance.
Normal fasting glucose does not rule out early compensation; fasting insulin and HOMA-IR can reveal the pressure behind normal glucose.
Waist circumference, triglycerides, HDL, ApoB, fasting insulin, HbA1c, and sleep trends give a more complete picture than any single hormone test.
Strength training, adequate protein, post-meal walking, sleep treatment, and careful retesting are the highest-value first steps.
SuperAge helps connect lab, wearable, body-composition, and biological-age trends so the transition is visible earlier.

References

The Menopause Society. Perimenopause.
Kapoor E, Collazo-Clavell ML, Faubion SS. Weight gain in women at midlife: a concise review of the pathophysiology and strategies for management. Mayo Clinic Proceedings. 2017.
El Khoudary SR, et al. Body composition and cardiometabolic health across the menopause transition. Obstetrics and Gynecology Clinics of North America. 2021.
Kim C, et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabetic Medicine. 2017.
Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Archives of Internal Medicine. 2008.
Torrens JI, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in mid-life women: SWAN. Menopause. 2009.
American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: Standards of Care in Diabetes - 2026. Diabetes Care. 2026.
National Institute of Diabetes and Digestive and Kidney Diseases. Insulin resistance and prediabetes.